361 related articles for article (PubMed ID: 31019304)
1. Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport.
Coleman JA; Yang D; Zhao Z; Wen PC; Yoshioka C; Tajkhorshid E; Gouaux E
Nature; 2019 May; 569(7754):141-145. PubMed ID: 31019304
[TBL] [Abstract][Full Text] [Related]
2. Structure-based discovery of conformationally selective inhibitors of the serotonin transporter.
Singh I; Seth A; Billesbølle CB; Braz J; Rodriguiz RM; Roy K; Bekele B; Craik V; Huang XP; Boytsov D; Pogorelov VM; Lak P; O'Donnell H; Sandtner W; Irwin JJ; Roth BL; Basbaum AI; Wetsel WC; Manglik A; Shoichet BK; Rudnick G
Cell; 2023 May; 186(10):2160-2175.e17. PubMed ID: 37137306
[TBL] [Abstract][Full Text] [Related]
3. Control of serotonin transporter phosphorylation by conformational state.
Zhang YW; Turk BE; Rudnick G
Proc Natl Acad Sci U S A; 2016 May; 113(20):E2776-83. PubMed ID: 27140629
[TBL] [Abstract][Full Text] [Related]
4. The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters.
Bulling S; Schicker K; Zhang YW; Steinkellner T; Stockner T; Gruber CW; Boehm S; Freissmuth M; Rudnick G; Sitte HH; Sandtner W
J Biol Chem; 2012 May; 287(22):18524-34. PubMed ID: 22451652
[TBL] [Abstract][Full Text] [Related]
5. Ligand induced conformational changes of the human serotonin transporter revealed by molecular dynamics simulations.
Koldsø H; Autzen HE; Grouleff J; Schiøtt B
PLoS One; 2013; 8(6):e63635. PubMed ID: 23776432
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for action by diverse antidepressants on biogenic amine transporters.
Wang H; Goehring A; Wang KH; Penmatsa A; Ressler R; Gouaux E
Nature; 2013 Nov; 503(7474):141-5. PubMed ID: 24121440
[TBL] [Abstract][Full Text] [Related]
7. Extracellular loops of the serotonin transporter act as a selectivity filter for drug binding.
Esendir E; Burtscher V; Coleman JA; Zhu R; Gouaux E; Freissmuth M; Sandtner W
J Biol Chem; 2021 Jul; 297(1):100863. PubMed ID: 34118233
[TBL] [Abstract][Full Text] [Related]
8. Cholesterol binding to a conserved site modulates the conformation, pharmacology, and transport kinetics of the human serotonin transporter.
Laursen L; Severinsen K; Kristensen KB; Periole X; Overby M; Müller HK; Schiøtt B; Sinning S
J Biol Chem; 2018 Mar; 293(10):3510-3523. PubMed ID: 29352106
[TBL] [Abstract][Full Text] [Related]
9. Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing state of the transporter.
Jacobs MT; Zhang YW; Campbell SD; Rudnick G
J Biol Chem; 2007 Oct; 282(40):29441-7. PubMed ID: 17698848
[TBL] [Abstract][Full Text] [Related]
10. Multi-state Model-Based Identification of Cryptic Allosteric Sites on Human Serotonin Transporter.
Tu G; Xu B; Luo D; Liu J; Liu Z; Chen G; Xue W
ACS Chem Neurosci; 2023 May; 14(9):1686-1694. PubMed ID: 37067527
[TBL] [Abstract][Full Text] [Related]
11. Importance of the Extracellular Loop 4 in the Human Serotonin Transporter for Inhibitor Binding and Substrate Translocation.
Rannversson H; Wilson P; Kristensen KB; Sinning S; Kristensen AS; Strømgaard K; Andersen J
J Biol Chem; 2015 Jun; 290(23):14582-94. PubMed ID: 25903124
[TBL] [Abstract][Full Text] [Related]
12. The substrate import mechanism of the human serotonin transporter.
Chan MC; Selvam B; Young HJ; Procko E; Shukla D
Biophys J; 2022 Mar; 121(5):715-730. PubMed ID: 35114149
[TBL] [Abstract][Full Text] [Related]
13. Substrate and Inhibitor-Specific Conformational Changes in the Human Serotonin Transporter Revealed by Voltage-Clamp Fluorometry.
Söderhielm PC; Andersen J; Munro L; Nielsen AT; Kristensen AS
Mol Pharmacol; 2015 Oct; 88(4):676-88. PubMed ID: 26174773
[TBL] [Abstract][Full Text] [Related]
14. Chemical and structural investigation of the paroxetine-human serotonin transporter complex.
Coleman JA; Navratna V; Antermite D; Yang D; Bull JA; Gouaux E
Elife; 2020 Jul; 9():. PubMed ID: 32618269
[TBL] [Abstract][Full Text] [Related]
15. Mutational mapping and modeling of the binding site for (S)-citalopram in the human serotonin transporter.
Andersen J; Olsen L; Hansen KB; Taboureau O; Jørgensen FS; Jørgensen AM; Bang-Andersen B; Egebjerg J; Strømgaard K; Kristensen AS
J Biol Chem; 2010 Jan; 285(3):2051-63. PubMed ID: 19892699
[TBL] [Abstract][Full Text] [Related]
16. Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter.
Cozzi NV; Gopalakrishnan A; Anderson LL; Feih JT; Shulgin AT; Daley PF; Ruoho AE
J Neural Transm (Vienna); 2009 Dec; 116(12):1591-9. PubMed ID: 19756361
[TBL] [Abstract][Full Text] [Related]
17. Conformational dynamics of the human serotonin transporter during substrate and drug binding.
Möller IR; Slivacka M; Nielsen AK; Rasmussen SGF; Gether U; Loland CJ; Rand KD
Nat Commun; 2019 Apr; 10(1):1687. PubMed ID: 30976000
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanism of citalopram and cocaine interactions with neurotransmitter transporters.
Ravna AW; Sylte I; Dahl SG
J Pharmacol Exp Ther; 2003 Oct; 307(1):34-41. PubMed ID: 12944499
[TBL] [Abstract][Full Text] [Related]
19. X-ray structures and mechanism of the human serotonin transporter.
Coleman JA; Green EM; Gouaux E
Nature; 2016 Apr; 532(7599):334-9. PubMed ID: 27049939
[TBL] [Abstract][Full Text] [Related]
20. Identification of an allosteric modulator of the serotonin transporter with novel mechanism of action.
Kortagere S; Fontana AC; Rose DR; Mortensen OV
Neuropharmacology; 2013 Sep; 72():282-90. PubMed ID: 23632081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
